Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07684937 HL-300 Dermatitis, Atopic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07684937 clinical trial report covering HL-300, Phase 1, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07653685 TQB-2930 Advanced Colorectal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07653685 clinical trial report covering TQB-2930, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07657390 Nicotinamide riboside/Pterostilbene Cancer Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07657390 clinical trial report covering Nicotinamide riboside/Pterostilbene, Phase 1/2, endpoints, sponsor, geography, readout timing and development wh
Latest Hotspot
8 min read
NCT07660406 68Ga-RM26-RGD Keloid Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07660406 clinical trial report covering 68Ga-RM26-RGD, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07655622 Vebreltinib Locally Advanced Lung Non-Small Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07655622 clinical trial report covering Vebreltinib, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07660614 LTX-002 Amyotrophic Lateral Sclerosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07660614 clinical trial report covering LTX-002, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07658352 HP-002 B-cell lymphoma refractory Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07658352 clinical trial report covering HP-002, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07659704 Autologous CD19-directed CAR-T cells(University of Sao Paulo) Systemic Lupus Erythematosus Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07659704 clinical trial report covering Autologous CD19-directed CAR-T cells(University of Sao Paulo), Phase 1/2, endpoints, sponsor, geography, readout
Latest Hotspot
8 min read
NCT07663864 Luspatercept-AAMT Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07663864 clinical trial report covering Luspatercept-AAMT, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07662681 Famitinib Malate Salivary gland carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07662681 clinical trial report covering Famitinib Malate, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07662720 Axelopran Cancer Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07662720 clinical trial report covering Axelopran, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07662174 Sirolimus Cerebral Hemorrhage Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07662174 clinical trial report covering Sirolimus, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.